Author Correction Issued for MAGE-A4/MAGE-A8-Targeted TCR-Based Bispecific T Cell Engager Study
Key Insights
Nature Medicine published an Author Correction for a study on a MAGE-A4/MAGE-A8 (search)-targeted TCR-based bispecific T cell engager, indicating modifications to the original article.
The correction pertains to a bispecific T cell engager immunotherapy targeting MAGE-A4 and MAGE-A8 (search) antigens, which are cancer-testis antigens relevant to oncology drug development.
The original article is licensed under Creative Commons BY-NC-ND 4.0, permitting non-commercial sharing with appropriate attribution but prohibiting derivative works.
Nature Medicine has issued an Author Correction for a research article investigating a MAGE-A4/MAGE-A8 (search)-targeted TCR-based bispecific T cell engager. The correction notice, published under the journal's correction policy, signals that modifications have been made to the original publication to address errors or omissions identified post-publication.
The original study focuses on a bispecific T cell engager that leverages T cell receptor (TCR)-based targeting against MAGE-A4 and MAGE-A8 (search), two members of the melanoma-associated antigen (MAGE) family of cancer-testis antigens. These targets are of significant interest in immuno-oncology due to their restricted expression in normal tissues and upregulation in various malignancies.
The corrected article is distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. Under this license, readers are permitted to share, distribute, and reproduce the material in any medium or format for non-commercial purposes, provided appropriate credit is given to the original authors and source, and a link to the Creative Commons license is included. However, the license explicitly prohibits the sharing of adapted or derivative material based on the article.
In a separate notice, Nature Medicine also published an Author Correction for a study on teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma (search). That article is licensed under the more permissive Creative Commons Attribution 4.0 International (CC BY 4.0) license, which allows for use, sharing, adaptation, distribution, and reproduction in any medium or format, provided appropriate credit is given and any changes are indicated.
Both corrections reflect the journal's commitment to maintaining scientific accuracy and transparency in the published literature. The specific nature and extent of the corrections were not detailed in the available notices.